Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Prothena Corporation plc PRTA

Healthcare Biotechnology
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the... see more

Recent & Breaking News (NDAQ:PRTA)

Prothena to Report First Quarter 2024 Financial Results on May 8

Business Wire 1 day ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Business Wire April 15, 2024

Prothena to Participate in Upcoming Healthcare Conferences

Business Wire March 5, 2024

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Business Wire February 15, 2024

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Business Wire February 8, 2024

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Business Wire January 8, 2024

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Business Wire November 2, 2023

Prothena to Report Third Quarter 2023 Financial Results on November 2

Business Wire October 26, 2023

Prothena to Participate in Upcoming Healthcare Conferences

Business Wire August 31, 2023

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Business Wire August 3, 2023

Prothena to Report Second Quarter 2023 Financial Results on August 3

Business Wire July 27, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Proterra Inc. - PTRA

Newsfile July 23, 2023

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Business Wire July 17, 2023

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Business Wire July 11, 2023

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Business Wire July 10, 2023

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

Business Wire June 27, 2023

Prothena to Participate in Jefferies 2023 Healthcare Conference

Business Wire June 2, 2023

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

Business Wire May 16, 2023

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

Business Wire May 4, 2023

Prothena to Report First Quarter 2023 Financial Results on May 4

Business Wire April 27, 2023